MEXICO CITY, Oct. 10 /PRNewswire-FirstCall/ -- Genomma Lab Internacional,
S.A.B. de C.V. (BMV: LAB) ("Genomma" or "the Company"), a leading Mexican
over-the-counter pharmaceuticals and personal care products company announced
that it has no additional information related to today's stock price movements
and considers that the variation in the stock price was singularly due to
normal fluctuations due to the market conditions of recent days.
Additionally, Genomma reaffirms its sound financial structure in order to
face the current situation:
-- Genomma Lab has a considerable net cash position to fuel future growth.
-- Genomma Lab is not exposed to derivative instruments.
-- Genomma Lab does not have foreign currency denominated liabilities.
Due to its business model, strong capitalization and high profitability,
the Company relies on its solid market position to continue growing in the
coming years.
Company Description
Genomma Lab Internacional, S.A.B. de C.V. is one of the fastest growing
over-the-counter pharmaceutical and personal care products companies in Mexico
and has a growing international presence. Genomma develops, sells and markets
a broad range of premium branded products, many of which are leaders in the
categories in which they compete in terms of sales and market share. The
Company has significantly grown its revenue and profitability through a
combination of a successful new product development process, consumer-oriented
marketing, a broad retail distribution network and a low-cost, highly flexible
operating model.
Genomma's shares are listed on the Mexican Stock Exchange under the ticker
symbol "LAB".
Web Site: www.genommalab.com
SOURCE Genomma Lab Internacional, S.A.B. de C.V.
Mexico City: Kristi King Etchberger, CFO, kking@genommalab.com, +55 5081 0000;
or NY: Maria Barona, +1-212-406-3691, mbarona@i-advize.com, or Kenia Vargas,
+1-212-406-3695, Genomma Lab Internacional, S.A.B. de C.V.
